Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tyra Biosciences, Inc.TYRA · Entity 4680 | Chief Discovery Officer | February 12, 2026 | February 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tyra Biosciences, Inc.
Report date February 12, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 146,981 |
Ending reported balance
After 2026-02-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-12 · Sale · Disposed 2,128 · Balance 152,853 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F2: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $31.02 to $31.75. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Row 2 · 2026-02-12 · Sale · Disposed 5,872 · Balance 146,981 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $32.98 to $33.85. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.
F2: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $31.02 to $31.75. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $32.98 to $33.85. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2026 Filed Feb 13, 2026 21:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 5,872 | $33.37 | $195,928.68 |
DisclosureSEC source: 0001193125-26-051534 · ownership.xml · nonDerivative · entry 2 Bensen Daniel · CIK 0001880946 · Chief Discovery Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $32.98 to $33.85. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| February 12, 2026 Filed Feb 13, 2026 21:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 2,128 | $31.50 | $67,035.83 |
DisclosureSEC source: 0001193125-26-051534 · ownership.xml · nonDerivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Discovery Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 152,853 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $31.02 to $31.75. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| January 12, 2026 Filed Jan 20, 2026 21:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 1,017 | $29.08 | $29,575.17 |
DisclosureSEC source: 0001193125-26-016651 · ownership.xml · nonDerivative · entry 2 Bensen Daniel · CIK 0001880946 · Chief Discovery Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $28.9131 to $29.23. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| January 12, 2026 Filed Jan 20, 2026 21:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 6,983 | $28.44 | $198,610.49 |
DisclosureSEC source: 0001193125-26-016651 · ownership.xml · nonDerivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Discovery Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 155,998 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $27.9083 to $28.84. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 21:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 8,000 | $22.64 | $181,159.20 |
DisclosureSEC source: 0001193125-25-320941 · ownership.xml · nonDerivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Discovery Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $22.06 to $23.03. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 00:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 49,956 | $16.32 | $815,296.91 |
DisclosureSEC source: 0001193125-25-288529 · ownership.xml · nonDerivative · entry 2 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.04 to $16.68. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 00:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 75,633 | $16.07 | $1,215,626.52 |
DisclosureSEC source: 0001193125-25-288529 · ownership.xml · nonDerivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 220,937 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.24. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 00:03 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 1,500 | $17.07 | $25,606.95 |
DisclosureSEC source: 0001193125-25-284935 · ownership.xml · nonDerivative · entry 4 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 296,570 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $17.06 to $17.09. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 00:03 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 18,572 | $16.11 | $299,191.21 |
DisclosureSEC source: 0001193125-25-284935 · ownership.xml · nonDerivative · entry 3 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 298,070 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $17.00. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 00:03 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 110,228 | $16.02 | $1,765,488.81 |
DisclosureSEC source: 0001193125-25-284935 · ownership.xml · nonDerivative · entry 2 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 316,642 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.13. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| November 13, 2025 Filed Nov 18, 2025 00:03 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 1,111 | $16.00 | $17,780.00 |
DisclosureSEC source: 0001193125-25-284935 · ownership.xml · nonDerivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 426,870 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.02. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| August 07, 2025 Filed Aug 7, 2025 20:40 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 170,000 | $0.00 Strike: $10.75 | $0.00 |
DisclosureSEC source: 0000950170-25-105140 · ownership.xml · derivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2035-08-06 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following August 7, 2025, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 21:55 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $21.57 | $0.00 |
DisclosureSEC source: 0000950170-24-098179 · ownership.xml · derivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2034-08-13 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following August 14, 2024, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| June 10, 2024 Filed Jun 10, 2024 23:10 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 3,502 | $20.00 | $70,044.90 |
DisclosureSEC source: 0000950170-24-071500 · ownership.xml · nonDerivative · entry 2 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 427,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022 F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $20.00 to $20.03. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 07, 2024 Filed Jun 10, 2024 23:10 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 200 | $20.00 | $4,000.00 |
DisclosureSEC source: 0000950170-24-071500 · ownership.xml · nonDerivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 431,483 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022 Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 21:46 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 200 | $20.00 | $4,000.00 |
DisclosureSEC source: 0000950170-24-030932 · ownership.xml · nonDerivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 431,683 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 22:38 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 68 | $20.00 | $1,360.00 |
DisclosureSEC source: 0000950170-24-028807 · ownership.xml · nonDerivative · entry 2 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 431,883 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 22:38 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 1,733 | $20.09 | $34,819.44 |
DisclosureSEC source: 0000950170-24-028807 · ownership.xml · nonDerivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 431,951 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $20.00 to $20.39. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| March 05, 2024 Filed Mar 5, 2024 22:40 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 1,189 | $20.02 | $23,802.47 |
DisclosureSEC source: 0000950170-24-026365 · ownership.xml · nonDerivative · entry 3 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 433,684 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $20.00 to $20.10. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 22:40 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 5,063 | $20.08 | $101,653.90 |
DisclosureSEC source: 0000950170-24-026365 · ownership.xml · nonDerivative · entry 2 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 434,873 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $20.00 to $20.44. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:40 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 2,900 | $20.04 | $58,111.94 |
DisclosureSEC source: 0000950170-24-026365 · ownership.xml · nonDerivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 439,936 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $20.00 to $20.14. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| February 29, 2024 Filed Feb 29, 2024 23:58 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 2,050 | $20.00 | $41,003.28 |
DisclosureSEC source: 0000950170-24-023406 · ownership.xml · nonDerivative · entry 3 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 442,836 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $20.00 to $20.02. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 23:58 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 5,849 | $20.13 | $117,728.67 |
DisclosureSEC source: 0000950170-24-023406 · ownership.xml · nonDerivative · entry 2 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 444,886 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $20.00 to $20.50. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 23:58 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 745 | $20.00 | $14,900.00 |
DisclosureSEC source: 0000950170-24-023406 · ownership.xml · nonDerivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 450,735 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. Read SEC document |
| February 12, 2024 Filed Feb 15, 2024 02:00 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 1,501 | $20.00 | $30,020.00 |
DisclosureSEC source: 0000950170-24-015559 · ownership.xml · nonDerivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 451,480 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. Read SEC document |
| February 07, 2024 Filed Feb 10, 2024 00:26 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 9,587 | $18.09 | $173,466.22 |
DisclosureSEC source: 0000950170-24-013474 · ownership.xml · nonDerivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 452,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $18.00 to $18.48. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 01:23 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 15,413 | $18.09 | $278,827.34 |
DisclosureSEC source: 0000950170-24-011880 · ownership.xml · nonDerivative · entry 4 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 462,568 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $18.00 to $18.44. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| February 02, 2024 Filed Feb 7, 2024 01:23 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,393 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0000950170-24-011880 · ownership.xml · derivative · entry 5 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,110 Underlying: Common Stock · 25,393 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| February 02, 2024 Filed Feb 7, 2024 01:23 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 2,300 | $17.04 | $39,198.90 |
DisclosureSEC source: 0000950170-24-011880 · ownership.xml · nonDerivative · entry 3 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 477,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $17.00 to $17.17. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| February 02, 2024 Filed Feb 7, 2024 01:23 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 73,093 | $16.31 | $1,191,898.31 |
DisclosureSEC source: 0000950170-24-011880 · ownership.xml · nonDerivative · entry 2 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 480,281 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.91. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| February 02, 2024 Filed Feb 7, 2024 01:23 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 25,393 | $0.61 | $15,489.73 |
DisclosureSEC source: 0000950170-24-011880 · ownership.xml · nonDerivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 553,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 28, 2023 Filed Aug 1, 2023 21:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001209191-23-044027 · doc4.xml · derivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2033-07-27 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following July 28, 2023, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| July 21, 2023 Filed Jul 22, 2023 00:52 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,900 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-043165 · doc4.xml · derivative · entry 6 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,503 Underlying: Common Stock · 3,900 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| July 21, 2023 Filed Jul 22, 2023 00:52 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 3,900 | $16.01 | $62,427.69 |
DisclosureSEC source: 0001209191-23-043165 · doc4.xml · nonDerivative · entry 4 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.07. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| July 21, 2023 Filed Jul 22, 2023 00:52 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 3,900 | $0.61 | $2,379.00 |
DisclosureSEC source: 0001209191-23-043165 · doc4.xml · nonDerivative · entry 3 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 531,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 19, 2023 Filed Jul 22, 2023 00:52 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 207 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-043165 · doc4.xml · derivative · entry 5 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,403 Underlying: Common Stock · 207 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| July 19, 2023 Filed Jul 22, 2023 00:52 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 207 | $16.08 | $3,327.53 |
DisclosureSEC source: 0001209191-23-043165 · doc4.xml · nonDerivative · entry 2 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. Read SEC document |
| July 19, 2023 Filed Jul 22, 2023 00:52 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 207 | $0.61 | $126.27 |
DisclosureSEC source: 0001209191-23-043165 · doc4.xml · nonDerivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 528,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 17, 2023 Filed Jul 17, 2023 23:35 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,900 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-042495 · doc4.xml · derivative · entry 6 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,610 Underlying: Common Stock · 1,900 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| July 17, 2023 Filed Jul 17, 2023 23:35 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 1,900 | $16.03 | $30,464.03 |
DisclosureSEC source: 0001209191-23-042495 · doc4.xml · nonDerivative · entry 4 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.10. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| July 17, 2023 Filed Jul 17, 2023 23:35 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 1,900 | $0.61 | $1,159.00 |
DisclosureSEC source: 0001209191-23-042495 · doc4.xml · nonDerivative · entry 3 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 529,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 23:35 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 500 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-042495 · doc4.xml · derivative · entry 5 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,510 Underlying: Common Stock · 500 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 23:35 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 500 | $16.13 | $8,065.00 |
DisclosureSEC source: 0001209191-23-042495 · doc4.xml · nonDerivative · entry 2 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.05 and $16.25. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 23:35 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 500 | $0.61 | $305.00 |
DisclosureSEC source: 0001209191-23-042495 · doc4.xml · nonDerivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 528,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 12, 2023 Filed Jul 12, 2023 22:41 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 201 | $16.23 | $3,262.31 |
DisclosureSEC source: 0001209191-23-042114 · doc4.xml · nonDerivative · entry 6 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.07 to $16.39. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| July 12, 2023 Filed Jul 12, 2023 22:41 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 201 | $0.61 | $122.61 |
DisclosureSEC source: 0001209191-23-042114 · doc4.xml · nonDerivative · entry 5 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 528,182 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 11, 2023 Filed Jul 12, 2023 22:41 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 201 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-042114 · doc4.xml · derivative · entry 9 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,010 Underlying: Common Stock · 201 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| July 11, 2023 Filed Jul 12, 2023 22:41 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 500 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-042114 · doc4.xml · derivative · entry 8 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,211 Underlying: Common Stock · 500 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| July 11, 2023 Filed Jul 12, 2023 22:41 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 500 | $16.02 | $8,009.50 |
DisclosureSEC source: 0001209191-23-042114 · doc4.xml · nonDerivative · entry 4 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.06. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| July 11, 2023 Filed Jul 12, 2023 22:41 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 500 | $0.61 | $305.00 |
DisclosureSEC source: 0001209191-23-042114 · doc4.xml · nonDerivative · entry 3 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 528,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.